Compugen (CGEN) Common Equity (2009 - 2026)
Compugen (CGEN) posted quarterly Common Equity of $95.4 million for Q1 2026, up 66.97% year-over-year from $57.1 million in Q1 2025, and down 7.18% on a QoQ basis from $102.7 million in Q4 2025.
Compugen (CGEN) Common Equity (2009 - 2026) Analysis & Trends
Compugen has reported Common Equity for 18 years, with the latest figure at $95.4 million in Q1 2026.
- Common Equity for Q1 2026 came in at $95.4 million, up 66.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $95.4 million (up 66.97% YoY), and the FY2025 annual result was $102.7 million, up 87.08% from the prior year.
- Common Equity declined to $95.4 million in Q1 2026, from $102.7 million in the prior quarter.
- Over five years, Common Equity peaked at $102.7 million in Q4 2025 and troughed at $43.8 million in Q3 2025.
- A 5-year average of $69.3 million and a median of $62.0 million in 2023 frame the typical range for Common Equity.
- The widest annual swing landed in 2023, when Common Equity sank 33.32%; it then surged 87.08% in 2025.
- A 5-year view of Common Equity shows it stood at $77.7 million in 2022, then fell by 15.6% to $65.6 million in 2023, then declined by 16.24% to $54.9 million in 2024, then soared by 87.08% to $102.7 million in 2025, then fell by 7.18% to $95.4 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $95.4 million in Q1 2026, $102.7 million in Q4 2025, and $43.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Compugen | 227.88 Mn | 136.13 Mn | 352,000.00 | 95.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.35 Mn |
| Dec 31, 2025 | 102.73 Mn |
| Sep 30, 2025 | 43.83 Mn |
| Jun 30, 2025 | 50.26 Mn |
| Mar 31, 2025 | 57.11 Mn |
| Dec 31, 2024 | 54.91 Mn |
| Sep 30, 2024 | 60.49 Mn |
| Jun 30, 2024 | 58.34 Mn |
| Mar 31, 2024 | 59.68 Mn |
| Dec 31, 2023 | 65.56 Mn |
| Sep 30, 2023 | 53.23 Mn |
| Jun 30, 2023 | 62.00 Mn |
| Mar 31, 2023 | 69.21 Mn |
| Dec 31, 2022 | 77.68 Mn |
| Sep 30, 2022 | 79.82 Mn |
| Jun 30, 2022 | 90.38 Mn |
| Mar 31, 2022 | 98.15 Mn |
| Dec 31, 2021 | 106.69 Mn |
| Sep 30, 2021 | 98.82 Mn |
| Jun 30, 2021 | 103.42 Mn |